GSEP
WVE icon

Golden State Equity Partners’s Wave Life Sciences WVE Stock Holding History

Golden State Equity Partners’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-90
Closed -$652 – 1763
2026
Q1 		$652 Buy
+90
New +$1.17K ﹤0.01% 1845

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GP
GSK plc London $602M AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

Golden State Equity Partners's WVE Position: Q2 2026 in Review

Golden State Equity Partners sold out of Wave Life Sciences (WVE) in Q2 2026, closing a stake of 90 shares — an estimated $652 sold.

Golden State Equity Partners first reported a position in WVE in Q1 2026 and held it in 1 quarter. The position peaked at $652 in Q1 2026. 239 funds tracked by Wall St. Rank hold WVE as of Q2 2026.

  • Golden State Equity Partners reported no remaining Wave Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 90 Wave Life Sciences shares in Q2 2026, an estimated $652.
  • Golden State Equity Partners first reported a position in Wave Life Sciences in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Wave Life Sciences position peaked at $652 in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.